Posted by Michael Wonder on 04 Mar 2021
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with rare blood cancers in its final appraisal document.
In its final appraisal document, NICE said that clinical trial evidence for Poteligeo is ‘very uncertain’ as the drug was compared with vorinostat, a treatment that is not used or licensed in the UK.
